- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Aptose Biosciences Reports Q4 Loss
Biotech firm posts $7.8 million deficit in latest quarter
Mar. 31, 2026 at 10:18pm
Got story updates? Submit your updates here. ›
Aptose Biosciences Inc., a Toronto-based biotech company, reported a loss of $7.8 million in its fourth quarter, the company announced on Tuesday.
Why it matters
Aptose Biosciences is a clinical-stage company focused on developing therapies for cancers and other life-threatening diseases. Its quarterly financial results provide insight into the company's progress and challenges as it works to advance its drug pipeline.
The details
The $7.8 million loss reported by Aptose Biosciences for the fourth quarter was in line with analysts' expectations. The company did not provide additional details on the factors contributing to the quarterly deficit.
- Aptose Biosciences reported its Q4 results on March 31, 2026.
The players
Aptose Biosciences Inc.
A clinical-stage biotech company based in Toronto that is developing therapies for cancers and other life-threatening diseases.
The takeaway
As a clinical-stage biotech firm, Aptose Biosciences' quarterly financial performance is closely watched by investors and analysts as it works to advance its drug pipeline and bring new treatments to market.
